Wei-cong Lin, She-pei Tan, Sheng-fu Zhou, Xiao-jie Zheng, Wen-juan Wu, Kang-cheng Zheng. Binding Mechanism and Molecular Design of Benzimidazole/Benzothiazole Derivatives as Potent Abl T315I Mutant Inhibitors[J]. Chinese Journal of Chemical Physics , 2017, 30(4): 429-442. doi: 10.1063/1674-0068/30/cjcp1704066
Citation: Wei-cong Lin, She-pei Tan, Sheng-fu Zhou, Xiao-jie Zheng, Wen-juan Wu, Kang-cheng Zheng. Binding Mechanism and Molecular Design of Benzimidazole/Benzothiazole Derivatives as Potent Abl T315I Mutant Inhibitors[J]. Chinese Journal of Chemical Physics , 2017, 30(4): 429-442. doi: 10.1063/1674-0068/30/cjcp1704066

Binding Mechanism and Molecular Design of Benzimidazole/Benzothiazole Derivatives as Potent Abl T315I Mutant Inhibitors

doi: 10.1063/1674-0068/30/cjcp1704066
  • Received Date: 2017-04-10
  • Rev Recd Date: 2017-05-31
  • Despite the efficacy of imatinib therapy in chronic myelogenous leukemia, the development of drug-resistant Abl mutants, especially the most difficult overcoming T315I mutant, makes the search for new Abl T315I inhibitors a very interesting challenge in medicinal chemistry. In this work, a multistep computational framework combining the three dimensional quantitative structure-activity relationship (3D-QSAR), molecular docking, molecular dynamics (MD) simulation and binding free energy calculation, was performed to explore the structural requirements for the Abl T315I activities of benzimidazole/benzothiazole derivatives and the binding mechanism between the inhibitors and Abl T315I. The established 3D-QSAR models exhibited satisfactory internal and external predictability. Docking study elucidated the comformations of compounds and the key amino acid residues at the binding pocket, which were confirmed by MD simulation. The binding free energies correlated well with the experimental activities. The MM-GBSA energy decomposition revealed that the van der Waals interaction was the major driving force for the interaction between the ligands and Abl T315I. The hydrogen bond interactions between the inhibitors and Met318 also played an important role in stablizing the binding of compounds to Abl T315I. Finally, four new compounds with rather high Abl T315I activities were designed and presented to experimenters for reference.
  • 加载中
  • [1] S. Faderl, H. M. Kantarjian, and M. Talpaz, Oncology (Williston Park) 13, 169(1999).
    [2] A. Quintás-Cardama and J. Cortes, Blood 113, 1619(2009).
    [3] E. Jabbour, J. Cortes, and H. Kantarjian, Targeted Oncol. 4, 3(2009).
    [4] A. Quintás-Cardama and J. Cortes, Clin. Cancer Res. 14, 4392(2008).
    [5] K. Mayer, G. Gielen, W. Willinek, M. Müller, and D. Wolf, Leukemia 28, 976(2014).
    [6] A. Desogus, S. Schenone, C. Brullo, C. Tintori, and F. Musumeci, Expert. Opin. Ther. Pat. 4, 1(2015).
    [7] J. Seymour, D. Kim, E. Rubin, A. Haregewoin, J. Clark, P. Watson, T. Hughes, I. Dufva, J. Jimenez, and F. Mahon, Blood Cancer J. 4, e238(2014).
    [8] S. Hong, J. Kim, S. M. Yun, H. Lee, Y. Park, S. S. Hong, and S. Hong, J. Med. Chem. 56, 3531(2013).
    [9] G. H. Zeng, W. J. Wu, R. Zhang, J. Xun, W. G. Xie, and Y. Shen, Chin. J. Chem. Phys. 25, 297(2012).
    [10] S. F. Zhou, S. P. Tan, D. Q. Fang, R. Zhang, W. C. Lin, W. J. Wu, RSC Adv. 6, 85355(2016).
    [11] M. Rasheed, C. Richter, L. T. Chisty, J. Kirkpatrick, M. Blackledge, M. R. Webb, and P. C. Driscoll, Biochemistry 53, 1092(2014).
    [12] Y. F. Ye, C. F. Fu, and S. X. Tian, Chin. J. Chem. Phys. 30, 25(2017).
    [13] S. Version, SYBYL 6.9 CP, St. Louis Tripos Associates, Inc., (2001).
    [14] M. D. M. AbdulHameed, A. Hamza, J. Liu, and C. G. Zhan, J. Chem. Inf. Model. 48, 1760(2008).
    [15] S. J. Cho and A. Tropsha, J. Med. Chem. 38, 1060(1995).
    [16] R. D. Cramer, D. E. Patterson, and J. D. Bunce, J. Am. Chem. Soc. 110, 5959(1988).
    [17] M. Hao, Y. Li, Y. Wang, Y. Yan, and S. Zhang, J. Chem. Inf. Model. 51, 2560(2011).
    [18] Y. Yang, J. Qin, H. Liu, and X. Yao, J. Chem. Inf. Model. 51, 680(2011).
    [19] D. A. Case, T. Darden,T. E. Cheatham Ⅲ, C. Simmerling, J. Wang, R. E. Duke, R. Luo, K. M. Merz, D. A. Pearlman, and M. Crowley, AMBER 9, San Francisco: University of California, 45(2006).
    [20] D. A. Case, T. E. Cheatham, T. Darden, H. Gohlke, R. Luo, K. M. Merz, A. Onufriev, C. Simmerling, B. Wang, and R. J. Woods, J. Comput. Chem. 26, 1668(2005).
    [21] J. Wang, R. M. Wolf, J. W. Caldwell, P. A. Kollman, and D. A. Case, J. Comput. Chem. 25, 1157(2004).
    [22] A. Jakalian, D. B. Jack, and C. I. Bayly, J. Comput. Chem. 23, 1623(2002).
    [23] U. Essmann, L. Perera, M. L. Berkowitz, T. Darden, H. Lee, and L. G. Pedersen, J. Chem. Phys. 103, 8577(1995).
    [24] H. C. Andersen, J. Comput. Phys. 52, 24(1983).
    [25] F. Fogolari, A. Brigo, and H. Molinari, Biophys. J. 85, 159(2003).
    [26] A. Onufriev, D. Bashford, and D. A. Case, Proteins: Structure, Function, and Bioinformatics 55, 383(2004).
    [27] M. Shen, S. Zhou, Y. Li, P. Pan, L. Zhang, and T. Hou, Mol. Biosyst. 9, 361(2013).
    [28] H. Gohlke, C. Kiel, and D. A. Case, J. Mol. Biol. 330, 891(2003).
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Article Metrics

Article views(687) PDF downloads(433) Cited by()

Proportional views
Related

Binding Mechanism and Molecular Design of Benzimidazole/Benzothiazole Derivatives as Potent Abl T315I Mutant Inhibitors

doi: 10.1063/1674-0068/30/cjcp1704066

Abstract: Despite the efficacy of imatinib therapy in chronic myelogenous leukemia, the development of drug-resistant Abl mutants, especially the most difficult overcoming T315I mutant, makes the search for new Abl T315I inhibitors a very interesting challenge in medicinal chemistry. In this work, a multistep computational framework combining the three dimensional quantitative structure-activity relationship (3D-QSAR), molecular docking, molecular dynamics (MD) simulation and binding free energy calculation, was performed to explore the structural requirements for the Abl T315I activities of benzimidazole/benzothiazole derivatives and the binding mechanism between the inhibitors and Abl T315I. The established 3D-QSAR models exhibited satisfactory internal and external predictability. Docking study elucidated the comformations of compounds and the key amino acid residues at the binding pocket, which were confirmed by MD simulation. The binding free energies correlated well with the experimental activities. The MM-GBSA energy decomposition revealed that the van der Waals interaction was the major driving force for the interaction between the ligands and Abl T315I. The hydrogen bond interactions between the inhibitors and Met318 also played an important role in stablizing the binding of compounds to Abl T315I. Finally, four new compounds with rather high Abl T315I activities were designed and presented to experimenters for reference.

Wei-cong Lin, She-pei Tan, Sheng-fu Zhou, Xiao-jie Zheng, Wen-juan Wu, Kang-cheng Zheng. Binding Mechanism and Molecular Design of Benzimidazole/Benzothiazole Derivatives as Potent Abl T315I Mutant Inhibitors[J]. Chinese Journal of Chemical Physics , 2017, 30(4): 429-442. doi: 10.1063/1674-0068/30/cjcp1704066
Citation: Wei-cong Lin, She-pei Tan, Sheng-fu Zhou, Xiao-jie Zheng, Wen-juan Wu, Kang-cheng Zheng. Binding Mechanism and Molecular Design of Benzimidazole/Benzothiazole Derivatives as Potent Abl T315I Mutant Inhibitors[J]. Chinese Journal of Chemical Physics , 2017, 30(4): 429-442. doi: 10.1063/1674-0068/30/cjcp1704066
Reference (28)

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return